Salt of substituted urea derivative and use thereof in medicine

1. A pharmaceutically acceptable acid addition salt of compound (I),

wherein the acid addition salt is:

benzene sulfonate crystalline I that has an X-ray powder diffraction pattern comprising one or more peaks expressed as 2θ at 6.74°±0.2°, 17.30°±0.2°, 18.98°±0.2°, 22.27°±0.2°, and 22.64°±0.2°; or

benzene sulfonate crystalline II that has an X-ray powder diffraction pattern comprising one or more peaks expressed as 2θ at 6.14°±0.2°, 17.10°±0.2°, 18.23°±0.2°, 21.63°±0.2°, and 22.49°±0.2°; or

benzene sulfonate crystalline III that has an X-ray powder diffraction pattern comprising one or more peaks expressed as 2θ at 6.12°±0.2°, 16.93°+0.2°, 17.92°+0.2°, 21.67°±0.2°, and 22.60°±0.2°; or

benzene sulfonate crystalline IV that has an X-ray powder diffraction pattern comprising one or more peaks expressed as 2θ at 17.01°±0.2°, 18.08°±0.2°, 21.10°±0.2°, 22.47°±0.2°, and 22.77°±0.2°; or

benzene sulfonate crystalline V that has an X-ray powder diffraction pattern comprising one or more peaks expressed as 2θ at 6.49°±0.2°, 17.28°±0.2°, 18.50°±0.2°, 19.57°±0.2°, and 23.60°±0.2°.

2. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline I and the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 10.95°±0.2°, 21.56°±0.2°, 21.91°±0.2°, 23.23°±0.2°, and 23.89°±0.2°.

3. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline I and the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 7.16°±0.2°, 10.95°±0.2°, 13.54°±0.2°, 14.33°±0.2°, 15.78°±0.2°, 16.46°±0.2°, 16.74°±0.2°, 17.82°±0.2°, 18.20°±0.2°, 18.46°±0.2°, 18.69°±0.2°, 19.21°±0.2°, 19.47°±0.2°, 19.72°±0.2°, 20.14°±0.2°, 20.49°±0.2°, 20.98°±0.2°, 21.56°±0.2°, 21.91°±0.2°, 23.23°±0.2°, 23.89°±0.2°, 24.45°±0.2°, 24.60°±0.2°, 25.46°±0.2°, 26.28°±0.2°, 26.53°±0.2°, 26.98°±0.2°, 27.30°±0.2°, 27.71°±0.2°, 28.38°±0.2°, 29.09°±0.2°, 29.47°±0.2°, 30.11°±0.2°, 30.74°±0.2°, 31.28°±0.2°, 31.54°±0.2°, 33.26°±0.2°, 33.85°±0.2°, 34.60°±0.2°, 35.36°±0.2°, 35.74°±0.2°, and 36.69°±0.2°.

4. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline I, and the benzene sulfonate crystalline I has a differential scanning calorimetry thermogram comprising an endothermic peak at 189.55° C.±3° C.

5. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline I, and the benzene sulfonate crystalline I has an X-ray powder diffraction pattern that is substantially the same as shown in FIG. 3 .

6. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline I, and the benzene sulfonate crystalline I has a differential scanning calorimetry thermogram that is substantially the same as shown in FIG. 10 .

7. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline II and has at least one of the following characteristics:

(a) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 9.22°±0.2°, 17.49°±0.2°, 19.57°±0.2°, 20.18°±0.2°, and 21.23°±0.2°;

(b) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 6.66°±0.2°, 9.22°±0.2°, 12.31°±0.2°, 12.97°±0.2°, 15.33°±0.2°, 16.17°±0.2°, 16.48°±0.2°, 17.49°±0.2°, 18.53°±0.2°, 19.57°±0.2°, 20.18°±0.2°, 21.23°±0.2°, 23.69°±0.2°, 24.18°±0.2°, 24.66°±0.2°, 25.52°±0.2°, 26.46°±0.2°, 27.78°±0.2°, 28.34°±0.2°, 29.15°±0.2°, 30.64°±0.2°, 30.99°±0.2°, 32.45°±0.2°, 33.93°±0.2°, 34.70°±0.2°, 35.48°±0.2°, and 38.57°±0.2°;

(c) a differential scanning calorimetry thermogram comprising endothermic peaks at 167.42° C.±3° C. and 173.39° C.±3° C.;

(d) the X-ray powder diffraction pattern is substantially the same as shown in FIG. 4 ; and

(e) a differential scanning calorimetry thermogram that is substantially the same as shown in FIG. 11 .

8. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline III and has at least one of the following characteristics:

(a) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 15.33°±0.2°, 18.21°±0.2°, 18.46°±0.2°, 20.29°±0.2°, 21.38°±0.2°, and 22.99°±0.2°;

(b) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 6.61°±0.2°, 11.36°±0.2°, 11.89°±0.2°, 12.31°±0.2°, 12.72°±0.2°, 12.95°±0.2°, 13.17°±0.2°, 13.71°±0.2°, 14.64°±0.2°, 15.33°±0.2°, 16.49°±0.2°, 17.11°±0.2°, 18.21°±0.2°, 18.46°±0.2°, 19.49°±0.2°, 20.29°±0.2°, 21.38°±0.2°, 22.99°±0.2°, 24.10°±0.2°, 24.37°±0.2°, 24.89°±0.2°, 25.61°±0.2°, 26.52°±0.2°, 27.63°±0.2°, 28.03°±0.2°, 29.07°±0.2°, 29.49°±0.2°, 30.22°±0.2°, 30.92°±0.2°, 31.16°±0.2°, 32.55°±0.2°, 33.53°±0.2°, 34.96°±0.2°, 37.51°±0.2°, and 38.94°±0.2°;

(c) a differential scanning calorimetry thermogram comprising an endothermic peak at 139.64° C.±3° C.;

(d) the X-ray powder diffraction pattern is substantially the same as shown in FIG. 5 ; and

(e) a differential scanning calorimetry thermogram that is substantially the same as shown in FIG. 12 .

9. The acid addition salt of claim 1 , wherein the salt is the benzene sulfonate crystalline IV or the benzene sulfonate crystalline V;

when the salt is the benzene sulfonate crystalline IV, the salt has at least one of the following characteristics:

(a) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 16.42°±0.2°, 18.31°±0.2°, 19.34°±0.2°, 20.05°±0.2°, and 27.75°±0.2°;

(b) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 6.07°±0.2°, 9.15°±0.2°, 11.28°±0.2°, 12.22°±0.2°, 12.47°±0.2°, 12.85°±0.2°, 13.71°±0.2°, 14.36°±0.2°, 15.21°±0.2°, 15.67°±0.2°, 16.11°±0.2°, 16.42°±0.2°, 17.38°±0.2°, 17.84°±0.2°, 18.31°±0.2°, 19.34°±0.2°, 19.47°±0.2°, 19.69°±0.2°, 20.05°±0.2°, 21.56°±0.2°, 21.80°±0.2°, 23.14°±0.2°, 23.68°±0.2°, 24.01°±0.2°, 24.29°±0.2°, 24.62°±0.2°, 25.34°±0.2°, 26.01°±0.2°, 26.36°±0.2°, 26.96°±0.2°, 27.48°±0.2°, 27.75°±0.2°, 28.23°±0.2°, 28.45°±0.2°, 29.06°±0.2°, 29.18°±0.2°, 29.40°±0.2°, 29.74°±0.2°, 30.48°±0.2°, 30.64°±0.2°, 31.07°±0.2°, 31.61°±0.2°, 32.56°±0.2°, 33.16°±0.2°, and 33.44°±0.2°;

(c) a differential scanning calorimetry thermogram comprising endothermic peaks at 160.59° C.±3° C. and 203.47° C.±3° C.;

(d) the X-ray powder diffraction pattern is substantially the same as shown in FIG. 6 ; and

(e) a differential scanning calorimetry thermogram that is substantially the same as shown in FIG. 13 ; or

when the salt is the benzene sulfonate crystalline V, the salt has at least one of the following characteristics:

(1) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 20.16°±0.2°, 21.66°±0.2°, 22.24°±0.2°, 22.60°±0.2°, and 23.13°±0.2°;

(2) the X-ray powder diffraction pattern further comprises one or more peaks expressed as 2θ at 9.62°±0.2°, 12.08°±0.2°, 13.04°±0.2°, 14.22°±0.2°, 14.60°±0.2°, 14.87°±0.2°, 15.90°±0.2°, 16.33°±0.2°, 16.66°±0.2°, 18.18°±0.2°, 20.16°±0.2°, 20.89°±0.2°, 21.66°±0.2°, 22.24°±0.2°, 22.60°±0.2°, 23.13°±0.2°, 23.60°±0.2°, 24.09°±0.2°, 24.33°±0.2°, 24.55°±0.2°, 25.17°±0.2°, 26.17°±0.2°, 27.08°±0.2°, 27.50°±0.2°, 28.73°±0.2°, 29.09°±0.2°, 29.62°±0.2°, 30.50°±0.2°, 31.62°±0.2°, 32.71°±0.2°, 33.87°±0.2°, 34.62°±0.2°, 36.64°±0.2°, 37.46°±0.2°, 38.22°±0.2°, and 39.94°±0.2°;

(3) a differential scanning calorimetry thermogram comprising an endothermic peak at 202.15° C.±3° C.;

(4) the X-ray powder diffraction pattern is substantially the same as shown in FIG. 7 ; and

(5) a differential scanning calorimetry thermogram that is substantially the same as shown in FIG. 14 .

10. A pharmaceutical composition comprising the acid addition salt of claim 1 , and a pharmaceutically acceptable carrier, excipient, diluent, adjuvant or a combination thereof.

11. The pharmaceutical composition of claim 10 further comprising at least one other active agent used for treating proliferative diseases, autoimmune diseases or inflammatory diseases, wherein the at least one other active agent is selected from the group consisting of chemotherapeutic drug, antiproliferative agent, immunosuppressor, immunologic stimulant, anti-inflammatory reagent, agent for treating atherosclerosis, agent for treating pulmonary fibrosis, CDK4/6 kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, and FLT3-ITD inhibitor.

12. The pharmaceutical composition of claim 10 further comprising at least one other active agent used for treating proliferative diseases, autoimmune diseases or inflammatory diseases, wherein the at least one other active agent is selected from the group consisting of chlorambucil, melphalan, cyclophosphamide, ifosfamide, busulfan, carmustine, lomustine, streptozotocin, cis-platinum, carboplatin, oxaliplatin, dacarbazine, temozolomide, procarbozine, methotrexate, fluorouracil, cytosine arabinoside, gemcitabine, purinethol, fludarabine, vinblastine, vincristine, vinorelbine, paclitaxel, docetaxel, topotecan, irinotecan, etoposide, trabectedin, dactinomycin, doxorubicin, pharmorubicin, daunomycin, mitoxantrone, bleomycin, mitomycin C, ixabepilone, tamoxifen, flutamide, gonadorelin analogue, megestrol acetate, prednisone, dexamethasone, methylprednisolone, thalidomide, interferon α, calcium folinate, sirolimus, temsirolimus, everolimus, afatinib, alisertib, amuvatinib, apatinib, axitinib, bortezomib, bosutinib, brivanib, cabozantinib, cediranib, crenolanib, crizotinib, dabrafenib, dacomitinib, danusertib, dasatinib, dovitinib, erlotinib, foretinib, ganetespib, gefitinib, ibrutinib, icotinib, imatinib, iniparib, lapatinib, lenvatinib, linifanib, linsitinib, masitinib, momelotinib, motesanib, neratinib, nilotinib, niraparib, oprozomib, olaparib, pazopanib, pictilisib, ponatinib, quizartinib, regorafenib, rigosertib, rucaparib, ruxolitinib, saracatinib, saridegib, sorafenib, sunitinib, tasocitinib, telatinib, tivantinib, tivozanib, tofacitinib, trametinib, vandetanib, veliparib, zelboraf, vismodegib, volasertib, alemtuzumab, bevacizumab, brentuximab vedotin, catumaxomab, cetuximab, denosumab, gemtuzumab, ipilimumab, nimotuzumab, ofatumumab, panitumumab, rituximab, tositumomab, trastuzumab, cabozantinib, ponatinib, midostaurin, pacritinib, gilteritinib, AKN-028, AT-9283, crenolanib, ENMD-2076, famitinib, dovitinib, PLX-3397, palbociclib, abemaciclib, ribociclib, rigosertib sodium, selinexor, roniciclib, AT-7519, seliciclib, and alvocidib.

13. A method of managing, treating, remitting or lessening proliferative diseases, autoimmune diseases or inflammatory diseases in a patient comprising administering the acid addition salt of claim 1 to the patient.

14. A method of managing, treating, remitting or lessening proliferative diseases, autoimmune diseases or inflammatory diseases in a patient comprising administering the pharmaceutical composition of claim 10 to the patient.

15. The method of claim 13 , wherein the proliferative disease is gastrointestinal stromal tumor, acute myelocytic leukemia, mutated chronic myeloid leukemia, acute lymphoblastic leukemia, leukaemia, chronic lymphocytic leukemia, primary macroglobulinemia, monocytic leukemia, leukemoid reaction, aplastic anemia, hemacelinosis, secondary or benign monoclonal gammopathy, colorectal cancer, gastric cancer, mammary cancer, lung cancer, liver cancer, prostatic cancer, pancreatic cancer, cancerous goiter, renal carcinoma, cerebroma, neck cancer, central nervous system cancer, malignant glioma, myeloproliferative disease, malignant histiocytosis, lymphoma, non lymphoreticular system tumor, multiple myeloma, granulocytic sarcoma, solitary plasmacytoma, malignant lymphoma, osteolytic lesion, lymphoblastoma, non-Hodgkin lymphoma, acute histiocytosis, Hodgkin's lymphoma, colon cancer, rectal cancer, small cell lung cancer, neuroblastoma, neuroendocrine cell tumor, islet cell tumor, medullary thyroid carcinoma, melanoma, retinoblastoma, uterine cancer, ovarian cancer, head and neck squamous cell carcinoma, alimentary canal malignancy, non-small cell lung cancer, cervical cancer, testiculoma, bladder cancer, myeloma or complications related to acute myelocytic leukemia;

the autoimmune disease is rheumatic arthritis, osteoarthralgia, lupus, multiple sclerosis, thyroiditis, type I diabetes, sarcoidosis, inflammatory bowel disease, Crohn's disease or systemic lupus;

the inflammatory disease is diverticulitis, colitis, pancreatitis, hepatitis, chronic hepatitis, cirrhosis, cholecystitis or chronic inflammation.

16. A drug combination comprising the acid addition salt of claim 1 and at least one other active agent used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the at least one other active agent is selected from the group consisting of chemotherapeutic drug, antiproliferative agent, immunosuppressor, immunologic stimulant, anti-inflammatory reagent, CDK4/6 kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, and FLT3-ITD inhibitor.

17. A drug combination comprising the pharmaceutical composition of claim 10 and at least one other active agent used for treating proliferative diseases, autoimmune diseases or inflammatory diseases; wherein the at least one other active agent is selected from the group consisting of chemotherapeutic drug, antiproliferative agent, immunosuppressor, immunologic stimulant, anti-inflammatory reagent, CDK4/6 kinase inhibitor, ABL inhibitor, ABL/Scr inhibitor, aurora kinase inhibitor, non-ATP competitive inhibitor of BCR-ABL, c-KIT mutation inhibitor, RET inhibitor, PDGFR inhibitor, VEGFR inhibitor, FLT3 inhibitor, and FLT3-ITD inhibitor.

18. A method of managing, treating, remitting or lessening a disease caused by mutation of c-KIT or mediation of RET, PDGFR, VEGFR, Bcr-ABL, FLT3 or FLT3-ITD in a patient, the method comprising administering the acid addition salt of claim 1 to the patient.